MedTrace Logo

PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer

NCT00362973 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2016-12-28

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as PET scans, may help in learning how well hormone therapy and trastuzumab work to kill breast cancer cells and allow doctors to plan better treatment.

PURPOSE: This clinical trial is studying how well PET scans work in assessing response to treatment in patients receiving hormone therapy or trastuzumab for breast cancer.

Conditions

Interventions

OTHER

laboratory biomarker analysis

PROCEDURE

needle biopsy

PROCEDURE

positron emission tomography

PROCEDURE

radionuclide imaging

RADIATION

fludeoxyglucose F 18

Sponsors & Collaborators

Principal Investigators

  • Hannah M. Linden, MD · Seattle Cancer Care Alliance

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362973 on ClinicalTrials.gov